Anteris Technologies Ltd
Anteris Technologies Ltd
Your view on AVR.AX
Overview
What the company does, where it operates, and who runs it.
About Anteris Technologies Ltd
- Industry
- Medical - Devices
- Sector
- Healthcare
- CEO
- Wayne Geoffrey Paterson
- Headquarters
- Toowong Tower, Level 3, Suite 302, 9 Sherwood Road, Toowong, QLD, AU
- Industry
- Medical - Devices
- Sector
- Healthcare
- CEO
- Wayne Geoffrey Paterson
- Headquarters
- Toowong Tower, Level 3, Suite 302, 9 Sherwood Road, Toowong, QLD, AU
Anteris Technologies Ltd is a firm specializing in the structural heart domain. It is responsible for the production and distribution of ADAPT, a product based on regenerative tissue technology. The company is also actively involved in advancing DurAVR™, an innovative 3D single-component aortic valve specifically designed for treating aortic stenosis. Additionally, Anteris allocates resources to the research and development of regenerative medicines. Founded in 1999, the enterprise was formerly known as Admedus Limited until it rebranded to Anteris Technologies Ltd in May 2020. Its primary operations are conducted from its base in Toowong, Australia.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks the stock is worth vs. the current price.
FRC's fair value estimate for Anteris Technologies Ltd, and the rating behind it. AVR.AX last traded at AUD 11.55; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Anteris Technologies Ltd. Starting points for Anteris Technologies Ltd: EPS -AUD 1.42, beta 0.73 — an Medical - Devices name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Anteris Technologies Ltd. Anteris Technologies Ltd does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Anteris Technologies Ltd. Trailing twelve-month EPS for Anteris Technologies Ltd stands at -AUD 1.42. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Anteris Technologies Ltd. Anteris Technologies Ltd has reported as a listed company since 2004. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Anteris Technologies Ltd valued side by side against its closest peers. Anteris Technologies Ltd is measured against Medical - Devices peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
Which funds and firms own the stock.
Which institutions hold Anteris Technologies Ltd, and how their positions are changing. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
Buying and selling by Anteris Technologies Ltd executives and directors. Shares of Anteris Technologies Ltd have traded between AUD 5.20 and AUD 15.47 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Anteris Technologies Ltd. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Anteris Technologies Ltd. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Anteris Technologies Ltd. Coverage tracks Anteris Technologies Ltd within Medical - Devices (Healthcare). Press releases and market coverage, newest first.